Planning Commission reviews Texas Star Pharmacy's proposed biosafety lab near local businesses

The Allen City Planning & Zoning Commission convened on March 18, 2025, to discuss a proposed development that could significantly impact the local community. The primary focus of the meeting was a request for zoning changes to allow for a biosafety level 2 laboratory, which would be part of a pharmaceutical manufacturing facility.

Commission members expressed concerns about the potential risks associated with the laboratory's proximity to nearby businesses and recreational facilities, including a gymnastics center and a gym. Questions were raised regarding noise and contamination risks, particularly given the nature of the materials that would be handled in the facility. One commissioner highlighted the importance of ensuring that the community remains safe from any potential hazards linked to the laboratory's operations.

The applicant, represented by Myron Dornick and Jason Claunch, assured the commission that the facility would primarily focus on research and development, with limited public access. They emphasized that the laboratory would not be manufacturing large quantities of hazardous materials, but rather working with stable compounds. However, concerns lingered about the implications of allowing a biosafety level 2 facility in such a densely populated area.

In response to the commission's apprehensions, the applicant indicated a willingness to adjust the laboratory's classification to a biosafety level 1, which would reduce the perceived risks. This proposal was met with cautious optimism, as it would address community concerns while allowing the project to move forward.

The commission also discussed the need for thorough reviews by health and safety departments should the project be approved. This would ensure compliance with all necessary regulations and standards, safeguarding the community's well-being.

As the meeting concluded, the commission faced a pivotal decision: to recommend the zoning changes with the adjusted biosafety level or to request further review. The outcome of this discussion will play a crucial role in shaping the future of pharmaceutical development in Allen, balancing economic growth with community safety.